A comprehensive view of Clinical Trials. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Chemicals Industry Market Intelligence Service.
'Tim-3 Antagonists For The Treatment And Diagnosis Of Cancers' in Patent Application Approval Process (USPTO 20240117044)
Published:
April 25, 2024
by NewsRx Pharma Business Daily
|
FDA accepts for priority review GSK’s application for an expanded indication of Jemperli dostarlimab-gxly plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer
Published:
April 24, 2024
by GSK Group (GlaxoSmithKline)
|
US Patent Issued to Regeneron Pharmaceuticals on April 23 for "Antigen binding molecule formats" (New York Inventors)
Published:
April 24, 2024
by U.S. Fed News
|
Sanofi's rilzabrutinib meets primary endpoint in Phase 3 LUNA 3 study for immune thrombocytopenia; potential for clinically beneficial treatment of several immune diseases underscored, with regulatory submissions in the US and EU expected by year-end
Published:
April 23, 2024
by Sanofi SA
|
INTERNATIONAL PATENT: REGENERON PHARMACEUTICALS, INC. FILES APPLICATION FOR "METHODS FOR REDUCING ALLOANTIBODY LEVELS IN SUBJECTS IN NEED OF SOLID ORGAN TRANSPLANTATION"
Published:
April 22, 2024
by U.S. Fed News
|
Ask us about our Chemicals Industry market view